BRAF and MEK inhibitors: Combination therapy delivers more durable outcomes in current studies

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In a review of clinical trials data for BRAF and MEK inhibitor combination therapy, combination therapy is generally delivering more durable outcomes than monotherapy, paradoxically with fewer side effects than monotherapy.

Study Design

  • Review of currentl...